Corcept Therapeutics Incorporated – NASDAQ:CORT

Add to watchlist

$71

+18.53

+35.32%

Market open

Closed in about 2 hours

+66.57%

month

+66.57%

quarter

+59.87%

year

Market Cap	5.22B
Enterprise value	2.31B

P/E	25.07
EV/Sales	5.75
EV/EBITDA	18.83
Price/Sales	5.91
Price/Book	4.73
PEG ratio	-12.15
EPS	1.15

Revenue	523.52M
EBITDA	123.67M
Income	118.02M
Revenue Q/Q	38.95%
Revenue Y/Y	26.51%

Profit margin	25.24%
Oper. margin	28.03%
Gross margin	98.66%
EBIT margin	28.03%
EBITDA margin	23.62%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Corcept Therapeutics Incorporated Stock Forecast

M Q Y

Last Year

$78

Potential upside: 9.85%

Analysts Price target
Financials & Ratios estimates

Corcept Therapeutics Incorporated (NASDAQ:CORT): Profit margin
Jun 2023	117.71M	27.52M	23.39%
Sep 2023	123.60M	31.37M	25.39%
Dec 2023	135.40M	31.35M	23.16%
Mar 2024	146.80M	27.76M	18.91%

Corcept Therapeutics Incorporated (NASDAQ:CORT): Debt to assets
Jun 2023	524625000	103.01M	19.64%
Sep 2023	594022000	132.34M	22.28%
Dec 2023	621517000	114.81M	18.47%
Mar 2024	655935000	108.07M	16.48%

Corcept Therapeutics Incorporated (NASDAQ:CORT): Cash Flow
Jun 2023	42.28M	-24.09M	-145.75M
Sep 2023	52.90M	-109.57M	-3.91M
Dec 2023	5.88M	17.09M	766K
Mar 2024	23.75M	-9.01M	-543K

Corcept Therapeutics Incorporated alternative data

Corcept Therapeutics Incorporated
Employees

Corcept Therapeutics Incorporated (NASDAQ:CORT): Employee count
Sep 2023	299
Oct 2023	299
Nov 2023	299
Dec 2023	299
Jan 2024	299
Feb 2024	299
Mar 2024	352
Apr 2024	352
May 2024	352
Jun 2024	352
Jul 2024	352

Corcept Therapeutics Incorporated
Hedge Funds Holdings Q1 2022

63.91% -0.47%

of CORT is owned by hedge funds

210 +9

hedge funds hold CORT stock

80.50M -62.13K

shares is hold by hedge funds

CORT hedge funds holdings changes

Corcept Therapeutics Incorporated
Insider Trading

Corcept Therapeutics Incorporated (NASDAQ:CORT): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	2200
Feb 2024	0	35028
Mar 2024	0	45372
Apr 2024	0	8143
May 2024	0	111257
Jun 2024	0	17200
Jul 2024	0	28200
Aug 2024	0	13251
Sep 2024	0	10000
Oct 2024	0	21000
Nov 2024	0	9614
Dec 2024	0	2200

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	10 Dec 2024	SWISHER DANIEL N JR director	Stock option (right to buy)	2,200	$12.13	$26,686
Option	10 Dec 2024	SWISHER DANIEL N JR director	Common Stock	2,200	$12.13	$26,686
Sale	10 Dec 2024	SWISHER DANIEL N JR director	Common Stock	2,200	$59.46	$130,812
Sale	22 Nov 2024	ROBB GARY CHARLES officer: Chief Bu..	Common Stock	2,609	$56.2	$146,626
Sale	22 Nov 2024	ROBB GARY CHARLES officer: Chief Bu..	Common Stock	2,609	$56.2	$146,626
Sale	22 Nov 2024	LYON JOSEPH DOUGLAS officer: See Remarks officer: See Remarks	Common Stock	1,411	$56.72	$80,032
Option	11 Nov 2024	SWISHER DANIEL N JR director	Stock option (right to buy)	2,200	$12.13	$26,686
Option	11 Nov 2024	SWISHER DANIEL N JR director	Common Stock	2,200	$12.13	$26,686
Sale	11 Nov 2024	SWISHER DANIEL N JR director	Common Stock	2,200	$59.88	$131,736
Option	4 Nov 2024	GUYER WILLIAM officer: Chief Development Officer officer: Chief Development Offi..	Stock option (right to buy)	3,394	$21.65	$73,480

CORT insider trading transactions

Corcept Therapeutics Incorporated
Patents

Status	Patent	Filling date	Issue date
Application	Application METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS Filling date: 22 Dec 2021 Issue date: 21 Jul 2022	22 Dec 2021	21 Jul 2022
Application	Application METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS Filling date: 20 Dec 2021 Issue date: 14 Jul 2022	20 Dec 2021	14 Jul 2022
Application	Application CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4 Filling date: 15 Feb 2022 Issue date: 16 Jun 2022	15 Feb 2022	16 Jun 2022
Grant	Grant Utility: Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 Filling date: 26 May 2021 Issue date: 29 Mar 2022	26 May 2021	29 Mar 2022
Application	Application Methods for Imaging and Treatment of Somatostatin-Receptor Positive Tumors Filling date: 19 Dec 2019 Issue date: 3 Mar 2022	19 Dec 2019	3 Mar 2022
Grant	Grant Utility: Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent Filling date: 17 Jan 2020 Issue date: 1 Feb 2022	17 Jan 2020	1 Feb 2022
Application	Application CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4 Filling date: 26 May 2021 Issue date: 2 Dec 2021	26 May 2021	2 Dec 2021
Application	Application CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C8 SUBSTRATES Filling date: 26 May 2021 Issue date: 2 Dec 2021	26 May 2021	2 Dec 2021
Application	Application CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C9 SUBSTRATES Filling date: 26 May 2021 Issue date: 2 Dec 2021	26 May 2021	2 Dec 2021
Application	Application POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS Filling date: 5 May 2021 Issue date: 25 Nov 2021	5 May 2021	25 Nov 2021

CORT patents

Corcept Therapeutics Incorporated
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 1 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 15 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 1 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

CORT earnings call transcripts

Corcept Therapeutics Incorporated
Executives

Insider	Age	Compensation
Dr. Joseph K. Belanoff (1957) Co-Founder, Pres, Chief Executive Officer & Director	68	$1,520,000
Mr. Gary Charles Robb (1963) Chief Bus. Officer & Sec.	62	$795,620
Mr. Sean Maduck (1977) Chief Commercial Officer	48	$688,540

Corcept Therapeutics Incorporated
Latest News

Thursday, 12 December 2024
16:05	Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes	businesswire.com
11:26	CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study	zacks.com
Wednesday, 11 December 2024
17:27	Corcept Therapeutics' ALS drug fails in mid-stage trial	reuters.com
16:05	Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)	businesswire.com
10:50	Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock	zacks.com
Monday, 9 December 2024
13:46	Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why	zacks.com
Friday, 6 December 2024
10:55	Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?	zacks.com
09:51	What Makes Corcept (CORT) a Good Fit for 'Trend Investing'	zacks.com
Friday, 29 November 2024
12:37	Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?	zacks.com
Wednesday, 27 November 2024
08:00	Corcept Therapeutics: A Most Promising And Compelling Biotech	seekingalpha.com
Monday, 25 November 2024
10:56	Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term	zacks.com
Friday, 22 November 2024
12:36	Corcept Shares Rise More Than 60% in Three Months: Here's Why	zacks.com
Thursday, 21 November 2024
13:46	3 Reasons Growth Investors Will Love Corcept (CORT)	zacks.com
Wednesday, 20 November 2024
10:55	Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet	zacks.com
09:50	Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable	zacks.com
Monday, 11 November 2024
08:51	Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance	zacks.com
Friday, 8 November 2024
08:21	5 Small Drug Stocks to Buy as Trump Gets Re-Elected	zacks.com
08:10	5 Stocks With Recent Price Strength to Tap Wall Street Rally	zacks.com
Wednesday, 6 November 2024
07:51	Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?	zacks.com
Tuesday, 5 November 2024
13:46	Here is Why Growth Investors Should Buy Corcept (CORT) Now	zacks.com
13:00	Corcept (CORT) Upgraded to Strong Buy: Here's Why	zacks.com
11:01	Best Momentum Stocks to Buy for November 5th	zacks.com
10:16	Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?	zacks.com
06:56	New Strong Buy Stocks for November 5th	zacks.com
Monday, 4 November 2024
10:55	Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade	zacks.com
09:50	Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why	zacks.com
Friday, 1 November 2024
13:20	Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?	zacks.com
Thursday, 31 October 2024
10:40	Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View	zacks.com
Wednesday, 30 October 2024
21:00	Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript	seekingalpha.com
19:01	Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates	zacks.com

Ideas & Opinions

Seeking Alpha 8 Aug 2025

Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early
Seeking Alpha 30 Jun 2025

Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Seeking Alpha 13 Jun 2025

Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
Seeking Alpha 22 Apr 2025

Corcept: Maintaining Strong Buy Even After Q4 Revenue And Earnings Miss
Seeking Alpha 15 Apr 2025

It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder
Seeking Alpha 22 Jan 2025

Corcept Therapeutics Generating Strong Revenue And Profit Growth
Seeking Alpha 11 Oct 2023

Amphastar Pharmaceuticals: Great Growth At A High Price
Seeking Alpha 26 Aug 2023

Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)
Seeking Alpha 28 Mar 2023

Xeris Biopharma: Picks And Shovels Play Has Long-Term Growth Potential
Seeking Alpha 7 Sep 2022

The Return On Equity Approach

Frequently Asked Questions (FAQ)

What's the price of Corcept Therapeutics Incorporated stock today?

One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $71.
When is Corcept Therapeutics Incorporated's next earnings date?

Unfortunately, Corcept Therapeutics Incorporated's (CORT) next earnings date is currently unknown.
Does Corcept Therapeutics Incorporated pay dividends?

No, Corcept Therapeutics Incorporated does not pay dividends.
How much money does Corcept Therapeutics Incorporated make?

Corcept Therapeutics Incorporated has a market capitalization of 5.22B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.04% to 482.38M US dollars.
What is Corcept Therapeutics Incorporated's stock symbol?

Corcept Therapeutics Incorporated is traded on the NASDAQ under the ticker symbol "CORT".
What is Corcept Therapeutics Incorporated's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Corcept Therapeutics Incorporated?

Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Corcept Therapeutics Incorporated's key executives?
Corcept Therapeutics Incorporated's management team includes the following people:
- Dr. Joseph K. Belanoff Co-Founder, Pres, Chief Executive Officer & Director(age: 68, pay: $1,520,000)
- Mr. Gary Charles Robb Chief Bus. Officer & Sec.(age: 62, pay: $795,620)
- Mr. Sean Maduck Chief Commercial Officer(age: 48, pay: $688,540)
Is Corcept Therapeutics Incorporated founder-led company?

Yes, Corcept Therapeutics Incorporated is a company led by its founder Dr. Joseph K. Belanoff.
How many employees does Corcept Therapeutics Incorporated have?

As Jul 2024, Corcept Therapeutics Incorporated employs 352 workers.
When Corcept Therapeutics Incorporated went public?

Corcept Therapeutics Incorporated is publicly traded company for more then 21 years since IPO on 14 Apr 2004.
What is Corcept Therapeutics Incorporated's official website?

The official website for Corcept Therapeutics Incorporated is corcept.com.
Where are Corcept Therapeutics Incorporated's headquarters?

Corcept Therapeutics Incorporated is headquartered at 149 Commonwealth Drive, Menlo Park, CA.
How can i contact Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated's mailing address is 149 Commonwealth Drive, Menlo Park, CA and company can be reached via phone at +65 03273270.
What is Corcept Therapeutics Incorporated stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Corcept Therapeutics Incorporated in the last 12 months, the avarage price target is $78. The average price target represents a 9.85% change from the last price of $71.

Corcept Therapeutics Incorporated

corcept.com

Exchange:

NASDAQ

Full time employees:

352

Industry:

Biotechnology

Sector:

Healthcare

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

+65 03273270

149 Commonwealth Drive
Menlo Park, CA 94025

CIK: 0001088856
ISIN: US2183521028
CUSIP: 218352102